Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 11Recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neuroblastoma 5Recurrence 2Multiple Myeloma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Transplant-Related Hematologic Malignancy 1Stomatitis 1Oligodendroglioma 1Neoplasms 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Carcinoma, Intraductal, Noninfiltrating 1Brain Neoplasms 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT07377435 2026-05-08

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

Beth Israel Deaconess Medical Center

Phase 1 Recruiting
25 enrolled
Plasma cell

Multiple Myeloma

NCT06799026 2026-05-07

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Beth Israel Deaconess Medical Center

Phase 1 Recruiting
25 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡